Adam Reno, DO
Family Medicine · Meridian, IDNPI 1841731155
Payments from drug & device makers
Across 146 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$394
- Pfizer$266
- Astellas Pharma US Inc$208
- AstraZeneca$195
- Sunovion Pharmaceuticals Inc.$140
- Grifols USA, LLC$124
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,31796%
- Education$1004%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 20 | $394 |
| Pfizer | 13 | $266 |
| Astellas Pharma US Inc | 14 | $208 |
| AstraZeneca | 14 | $195 |
| Sunovion Pharmaceuticals Inc. | 10 | $140 |
| Grifols USA, LLC | 7 | $124 |
| Johnson & Johnson | 8 | $113 |
| Novo Nordisk | 6 | $104 |
| Amgen | 4 | $96 |
| Bayer | 5 | $78 |
| Lilly USA, LLC | 5 | $76 |
| Boehringer Ingelheim | 4 | $61 |
| Eisai Inc. | 4 | $55 |
| Novartis | 3 | $52 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $52 |
| Amarin Pharma, Inc. | 3 | $47 |
| Acadia Pharmaceuticals Inc | 3 | $41 |
| Merck | 3 | $40 |
| Sanofi-aventis U.S. LLC | 2 | $38 |
| Corcept Therapeutics | 2 | $35 |
| Adlon Therapeutics L.p. | 2 | $32 |
| GSK | 2 | $30 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Abbott | 1 | $21 |
| Mylan Specialty L.p. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Biogen | 1 | $16 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Therapeuticsmd, Inc. | 1 | $16 |
| Scilex Pharmaceuticals Inc. | 1 | $14 |
How this compares
$2,417 in reported general payments places this provider in the 85th percentile of 803 family medicine providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 75 | $75,203 |
| EliquisApixaban | 87 | $66,132 |
| JardianceEmpagliflozin | 66 | $55,427 |
| MounjaroTirzepatide | 52 | $52,226 |
| Dupixent PenDupilumab | 13 | $48,647 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $31,577 |
| LinzessLinaclotide | 23 | $17,910 |
| FarxigaDapagliflozin Propanediol | 16 | $16,741 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $14,716 |
| JanuviaSitagliptin Phosphate | 24 | $14,578 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $7,889 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $7,252 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 34 | $5,292 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $4,997 |
| Gabapentin | 263 | $4,772 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $104 | $75,20375 claims |
| PfizerEliquis | $266 | $66,13287 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $61 | $62,68081 claims |
| Lilly USA, LLCMounjaro | $76 | $52,22652 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $30 | $51,29087 claims |
| AstraZenecaFarxiga, Symbicort | $195 | $20,07728 claims |
| AbbVieLinzess | $394 | $17,91023 claims |
| MerckJanuvia | $40 | $14,57824 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $14 | $1,59519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 803 family medicine providers in Idaho.
Other family medicine in Meridian
- Mark TurnerMeridian$40.5M
- David ButukMeridian$15.2M
- Elaine DavidsonMeridian$303K
- Timothy McHughMeridian$176K
- Mark JohnsonMeridian$10K
- Jason LudwigMeridian$7K
- Jacob SmithMeridian$7K
- Ginger AllenMeridian$6K
- George ThomasMeridian$6K
- Aaron MoorhouseMeridian$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.